Sildenafil in bronchopulmonary dysplasia-associated pulmonary hypertension: developmental and translational insights
Abstract
Bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH) is increasingly viewed as a developmental pulmonary vascular disorder rather than a purely reactive vasoconstrictive complication of chronic lung disease. It involves impaired angiogenesis, reduced pulmonary vascular surface area, alveolar simplification, and progressive right ventricle-pulmonary artery uncoupling. Sildenafil, a phosphodiesterase type 5 inhibitor, is widely used because it enhances nitric oxide-cyclic guanosine monophosphate signaling and may reduce pulmonary vascular tone. However, neonatal-specific evidence remains limited, dosing approaches are heterogeneous, and its long-term effects on vascular remodeling and clinical outcomes are uncertain. This narrative review integrates developmental biology, translational evidence, clinical studies, pharmacokinetics, and safety considerations to critically evaluate sildenafil in BPD-PH. Current data support short-term improvements in echocardiographic hemodynamics and oxygenation in selected infants, but do not demonstrate durable remodeling reversal or improved survival. Experimental studies suggest effects on endothelial survival, smooth muscle proliferation, angiogenic signaling, and oxidative stress, although relevance to human preterm infants remains incompletely validated. Developmental pharmacokinetics, including CYP3A maturation, weight, postnatal age, route, and drug interactions, contribute to variable exposure. Sildenafil use should…
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.